# Complications Related to Sexualized Drug Use: What Can We Learn From Literature?

Hélène Donnadieu-Rigole, Hélène Peyrière, Amine Benyamina, Laurent Karila

► To cite this version:

Hélène Donnadieu-Rigole, Hélène Peyrière, Amine Benyamina, Laurent Karila. Complications Related to Sexualized Drug Use: What Can We Learn From Literature?. Frontiers in Neuroscience, 2020, 14, 10.3389/fnins.2020.548704. [https://hal.science/hal-04890097v1](https://hal.science/hal-04890097v1)

HAL Id: hal-04890097

Submitted on 16 Jan 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for
updates

# Complications Related to Sexualized Drug Use: What Can We Learn From Literature?

Hélène Donnadieu-Rigole¹,², Hélène Peyrière²,³, Amine Benyamina⁴,⁵ and Laurent Karila⁴,⁵,⁶*

¹ Addictions Department, Saint Eloi Hospital, University Hospital of Montpellier, Montpellier, France, ² INSERM U 1058, Pathogenesis and Control of Chronic Infections (PCCI), Montpellier, France, ³ Addictovigilance Center, Department of Medical Pharmacology and Toxicology, University Hospital of Montpellier, Montpellier, France, ⁴ Centre d'Enseignement, de Recherche et de Traitement des Addictions, Hôpital Universitaire Paul-Brousse (APHP), Villejuif, France, ⁵ Paris-Saclay University, Saint-Aubin, France, ⁶ Unité de Recherche PSYCOMADD, Villejuif, France

Chemsex is described as the use of specific psychoactive substances (PS) during sexual activity to sustain, enhance, disinhibit or facilitate the sexual experience. It preferentially concerns men who have sex with men (MSM). They use new synthetic substances like cathinones, methamphetamines, gamma-butyrolactone/gamma-hydroxybutyrate (GBL/GHB), ketamine, and cocaine. The prevalence of chemsex varies from 3 to 31% during lifetime. The Internet has participated significantly in the evolution of sexual behaviors, both in terms of sexual dating and the availability of new synthetic substances. The advent of geolocation applications contributed to the development of chemsex. The literature describes many complications linked to these sexual practices; the main clinical effects related to cathinones consumption were psychiatric symptoms; agitation, hallucinations, anxiety, suicidal ideation, paranoia, and confusion. Regular GBL/GHB consumption alter cognitive functions, particularly memory and emotion management. Use of these drugs in party and play is dramatically associated with high-risk sexual behaviors. The prevalence of hepatitis B, hepatitis C syphilis, and HIV is higher in men who use methamphetamine and Viagra and/or who declared they practiced slamming, chemsex, and fisting. Other sexually transmitted infections (STIs) such as gonorrhea have increased with methamphetamine and GHB/GBL use. Actually, the care of individuals who practice Chemsex in a problematic way is currently not codified, but the use of integrative and specific interventions is necessary.

**Keywords:** psychoactive substances, sexual behaviors, cathinones, sexualized drug use, GBL/GHB

**OPEN ACCESS**

**Edited by:**
Liana Fattore,
National Research Council (CNR), Italy

**Reviewed by:**
Eugene A. Kiyatkin,
National Institute on Drug Abuse
(NIDA), United States
Anne Batisse,
Assistance Publique Hopitaux De
Paris, France

*Correspondence:
Laurent Karila
laurent.karila@aphp.fr;
laurent.karila@gmail.com

**Specialty section:**
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience

**Received:** 03 April 2020
**Accepted:** 09 November 2020
**Published:** 27 November 2020

**Citation:**
Donnadieu-Rigole H, Peyrière H, Benyamina A and Karila L (2020) Complications Related to Sexualized Drug Use: What Can We Learn From Literature? *Front. Neurosci.* 14:548704. doi: 10.3389/fnins.2020.548704

## INTRODUCTION

Drug use in a sexual context has been described since antiquity in order to improve sexual performance or to promote desinhibition. In this review we specifically studied the recent phenomenon of “chemsex” secondary to geolocation applications and new designer substances, which has increased exponentially since the 2000s. Numerous substances are linked to sex

**Abbreviations:** PS, psychoactive substances; BBV, bloodborne viruses; STI, sexually transmitted infections; MSM, men who have sex with men; EDDs, erectile disorder drugs.
use and they are associated with different populations and sexual behaviors. Alcohol, cannabis and MDMA (methylene-dioxyméthamphétamine) are more commonly used in heterosexual practices (Lawn et al., 2019), whereas men who have sex with men (MSM) use cathinones, methamphetamines, gamma-butyrolactone/gamma-hydroxybutyrate (GBL/GHB), ketamine, and cocaine. This behavior is referred to “chemsex” (formerly “sexualized drug use”). Chemsex is described as the use of specific psychoactive substances (PS) during sexual activity to sustain, enhance, disinhibit, or facilitate the sexual experience. (Giorgetti et al., 2017). The Internet has participated significantly in the evolution of sexual behaviors, both in terms of sexual dating and the availability of new synthetic substances. Chemsex is associated with a high risk of contraction of sexually transmitted infection (STI) and bloodborne viruses (BBV). The care of individuals who practice Chemsex in a problematic way is currently not codified. The objective of this review was to describe complications related to drug use in a sexual context in order to adapt specific care.

## METHODS

A review of the literature was conducted using PubMed. The search was carried out per theme using the keywords reported in **Table 1**.

These keywords were used alone or in association with the keyword “chemsex.” The **Table 1** shows the number of articles identified for each keyword and in association from 2000 to 2020. This technique has allowed to find many articles with keyword alone and/or association with the main keyword “chemsex.” We have selected those that seemed more relevant for this review about complications related to drug use (**Figure 1**). Original animal articles have been excluded.

## PREVALENCE

Currently, the prevalence of chemsex is difficult to estimate because its definition varies between countries (Schmidt et al., 2016). It varies from 3 to 31% during lifetime and from 0.4 to 16.3% the last month. The frequency of chemsex depending

on the city of residence and countries studied, and the taking into account or not of HIV-positive individuals (Elliot et al., 2017), the use of dating applications and the type of PS used (Maxwell et al., 2019).

Slamming is the term used for intravenous injection of these PS during party and play. In Australia, the prevalence of slamming is 10% in MSM, and in England it was found to be 16% in an MSM population diagnosed with *Shigella flexneri* 3a infection (Gilbart et al., 2015). Slamming is more common in MSM and women who have sex with women (WSW) than in libertine heterosexuals practicing chemsex (Heinsbroek et al., 2018). These differences in prevalence show how interesting it would be to define the practice of chemsex in an international way: target population, drugs used, and exclusion criteria.

## SEX MEETING APPLICATIONS

The practice of combining sex and PS has increased steadily with the development of mobile applications. The advent of geolocation applications in 1990 transformed the way gay and bisexual men meet (Grov et al., 2014) and contributed to the development of chemsex. These new applications allow to meet one or more partners very quickly in their surroundings and to express their sexual desires, and their preferences in the practice of chemsex. Sex meeting applications made it possible for “clubbers” and “sexers” to meet. These 2 populations did not have the same sexual practices. “Sexers” had harder practices and used drugs, which have since become widespread amongst MSM.

At least 40% of MSM and 68% of the youngest individuals (Garofalo et al., 2007) find their partners using the Internet. Finding a sex partner on Internet or using a mobile application increases condomless anal intercourse and the risk of HIV transmission (Lewnard and Berrang-Ford, 2014; Whitfield et al., 2017). Sociologists are worried about the disappearance of non-virtual meeting places associated with the development of phone applications and describe the increase of solitude felt by homosexuals (Renninger, 2018).

## DESIGNER SUBSTANCES AND ERECTILE DISORDER DRUGS (EDDs)

New designer substances appeared in the early 2000s and participated in the development of chemsex. New synthetic substances are detailed in the **Figure 2** and in the **Table 2**. The main complications are described in **Table 3**. Most of these studies come from emergency or intensive care.

### Synthetic Cathinones

The most used PS are synthetic cathinones, the leader of which being mephedrone or 4 MMC (4-methylmetcathinone). Their development was inspired by the Khat plant (*Catha edulis*) that is considered as a natural amphetamine and is used in certain countries of East Africa and the Arabian Peninsula (Kalix, 1990). These new designer substances are sold as bath salts “not for human consumption” to circumvent

<table><caption>**TABLE 1** | Keywords (from 2000 to 2020).</caption><thead><tr><th>Themes</th><th>Keywords</th><th>Alone/Association</th></tr></thead><tbody><tr><td rowspan="2">Sexual behavior</td><td>Chemsex</td><td>228</td></tr><tr><td>Slamming</td><td>52/9</td></tr><tr><td rowspan="10">Drugs</td><td>Cathinones</td><td>766/17</td></tr><tr><td>Mephedrone</td><td>830/77</td></tr><tr><td>Methamphetamine</td><td>335/123</td></tr><tr><td>GHB</td><td>1704/34</td></tr><tr><td>GBL</td><td>456/23</td></tr><tr><td>GBL/GHB</td><td>10/3</td></tr><tr><td>Ketamine</td><td>13 711/76</td></tr><tr><td>Erectile designer drugs (Sildenafil, Tadalafil, and Vardenafil)</td><td>2859/14</td></tr><tr><td>Applications</td><td>Sex meeting application</td><td>122/22</td></tr></tbody></table>
<figure><img src="image_3.png" /><figcaption>**FIGURE 1** | Flow chart.</figcaption></figure>

<figure><img src="image_4.png" /><figcaption>**FIGURE 2** | New designer drugs and their expected effects.</figcaption></figure>

the legislation (Coppola and Mondola, 2012). They belong to the phenylethylamine family (Petit et al., 2013) and are psychostimulants with an amphetamine- or cocaine-like effect. They generate agitation, euphoria, and empathy in users and increase libido and sexual performance.

These PS have a strong addictogenic effect with dependence levels of 30% according to DSM-IV criteria (Dargan et al., 2011; Winstock et al., 2011). The main acute complications are cardiac, psychiatric, and neurological, and they can be fatal (Busardo et al., 2015; Ezaki et al., 2016; Sande, 2016; Kronstrand et al., 2018; Riley et al., 2019; **Table 3**).

Blood levels in case of lethal intoxication are higher than in cases of non-lethal poisoning, and lethal situations arise from

the combining of several drugs (Papaseit et al., 2017). These substances have been classified as narcotics in Europe since 2010 (Forsyth, 2012) and it is currently illegal to purchase or possess them, but they are usually obtained on the Internet or directly during party and play. Cathinones take the form of a white powder or small crystals. They are taken orally, by snorting, intrarectally (booty bump), or by injection (slamming).

In the study of Spiller et al. (2011) the main clinical effects (>10%) related to cathinones consumption were agitation (82%), combative violent behavior (57%), tachycardia (56%), hallucinations (40%), paranoia (36%), confusion (34%), myoclonus (19%), hypertension (17%), chest pain (17%), and mydriasis (13%).
<table><caption>**TABLE 2** | New designer drugs and their expected effects.</caption><thead><tr><th>Drugs name</th><th>Common names</th><th>Expected effects</th><th>Way of administration</th></tr></thead><tbody><tr><td rowspan="4">Cathinones</td><td>MDPV</td><td>Psychostimulants<br/>amphetamine-like effect</td><td>Orally</td></tr><tr><td>4-MMC</td><td>Euphoria</td><td>Sniff</td></tr><tr><td>Mephedrone</td><td>Empathy</td><td>Intrarectally</td></tr><tr><td>4-MEC<br/>M-Cath</td><td>Increase libido and sexual<br/>performance</td><td>(booty bump)<br/>Injection</td></tr><tr><td rowspan="3">Methamphetamine</td><td>Meth</td><td>Powerful psychostimulant</td><td>Orally</td></tr><tr><td>Crystal<br/>Ice</td><td>Euphoria</td><td>Sniff</td></tr><tr><td></td><td>Empathy</td><td>Smoke<br/>Injection</td></tr><tr><td>GBL/GHB</td><td>"G"</td><td>Relaxation disinhibiting<br/>Increases desire facilitates<br/>penetration</td><td>Orally</td></tr><tr><td>Ketamine</td><td>"Ke"</td><td>Psychostimulant effect<br/>Euphoria</td><td>Sniff<br/>Orally</td></tr></tbody></table>

In another serie, main complications of cathinones related to chemsex were psychotic symptoms, agitation, anxiety, suicidal ideation, or suicide attempt (Batisse et al., 2014). More recently, severe psychiatric symptoms have been observed with ephylone, a recent available synthetic cathinones, in a context of chemsex (Serre et al., 2019).

Excited delirium has been reported with the use of synthetic cathinones, with a challenging combination of paranoia,

confusion, severe agitation, and violent behavior (Diestelmann et al., 2018; Schmoll et al., 2018). The presentation of these patients has been frequently complicated by evidence of skeletal muscle damage, dehydration, renal dysfunction, and hyperthermia that may lead to multiorgan failure and death. The precise pathophysiology underlying the syndrome of excited delirium is incompletely understood. However, the role of the central dopamine dysregulation, inducing a thermoregulation dysfunction has been suggested (Penders et al., 2012).

Cathinones are often combined with other illicit PS such as methamphetamine (Maxwell et al., 2019), GBL/GHB (Bourne et al., 2015; Edmundson et al., 2018), ketamine, and cocaine (Melendez-Torres et al., 2018b).

## Methamphetamine

Methamphetamine (crystal meth), like cocaine and amphetamines, inhibits the reuptake of monoamine transporters and stimulate the release of dopamine, noradrenaline, adrenaline, and serotonin (Liechti, 2015). Crystal is characterized by its stronger psychostimulant effects and its immense addictogenic potential. Use of this dangerous substance is mainly described in the United States and the United Kingdom (Degenhardt et al., 2010) with prevalence ranging from 27% (lifetime use) to 7% (recent use) (Benotsch et al., 2012). Methamphetamine can be swallowed, smoked, injected or intrarectally administered. Methamphetamine has been linked to a lot of cardiac, psychiatric, neuropsychological and dental effects (Table 3).

<table><caption>**TABLE 3** | Drugs and their main complications (without STI and BBV).</caption><thead><tr><th>Drugs</th><th>Main risks</th><th>Treatment</th><th>Studies</th><th>Number of subjects</th></tr></thead><tbody><tr><td rowspan="6">Cathinones</td><td rowspan="2">Psychiatric: panic attack, feeling of persecution, depression, confusion, hallucinations, suicide attempt or suicidal ideation, severe agitation, or violence</td><td>Psychiatric hospitalization</td><td>Batisse et al., 2014</td><td>21 subjects</td></tr><tr><td>Symptomatic treatment</td><td>Spiller et al., 2011</td><td>236 subjects</td></tr><tr><td>Cardiac: hypertension, tachycardia, and chest pain</td><td>Symptomatic treatment</td><td>Sande, 2016</td><td>249 subjects</td></tr><tr><td>Cardiac ischemia</td><td></td><td>Schmoll et al., 2018</td><td>96 subjects</td></tr><tr><td>Dependence</td><td></td><td>Diestelmann et al., 2018</td><td>50 subjects</td></tr><tr><td>Sympathomimetic syndrome and rhabdomyolysis</td><td></td><td></td><td></td></tr><tr><td rowspan="10">Methamphetamine</td><td rowspan="2">Cardiac: methamphetamine-associated cardiomyopathy, heart rhythm disturbance, acute coronary syndromes, pulmonary arterial hypertension, and hypertension</td><td>Intensive care</td><td>Ezaki et al., 2016</td><td>61 autopsy cases</td></tr><tr><td>Benzodiazepines</td><td>Spiller et al., 2011</td><td>236 subjects</td></tr><tr><td></td><td>Winstock et al., 2011</td><td>100 subjects</td></tr><tr><td></td><td>O'Connor et al., 2015</td><td>102 subjects</td></tr><tr><td>Psychiatric care</td><td>Froberg et al., 2015</td><td>23 subjects</td></tr><tr><td>β-blockers</td><td>Umebachi et al., 2016</td><td>8 subjects</td></tr><tr><td>Blockage of the renin-angiotensin system</td><td>Sevak et al., 2011</td><td>6 subjects</td></tr><tr><td>Aripiprazole</td><td>Neeki et al., 2018</td><td>449 subjects</td></tr><tr><td>Psychiatric: depression, confusion, acute psychosis and psychotic symptoms, and anxiety disorder</td><td>Antipsychotic medications</td><td>McKetin et al., 2013</td><td>278 subjects</td></tr><tr><td>Neuropsychological effects: alteration of executive functions, episodic memory, psychomotor functions, and complex information processing speed.</td><td>Benzodiazepines</td><td>Scott et al., 2007</td><td>Meta-analysis (18 studies)</td></tr><tr><td>Dependence</td><td>N-acetyl-cysteine</td><td>McKetin et al., 2019</td><td>180 subjects</td></tr><tr><td rowspan="3">GBL/GHB</td><td rowspan="2">Coma, presentation to an emergency department, and neurological complications</td><td></td><td>Shetty et al., 2015</td><td>571 subjects</td></tr><tr><td>Intensive care</td><td>Rommel et al., 2016</td><td>100 subjects</td></tr><tr><td>Dependence</td><td>Baclofen</td><td>Wood et al., 2013</td><td>158 subjects</td></tr><tr><td></td><td></td><td>Raposo Pereira et al., 2020</td><td>27 subjects</td></tr><tr><td></td><td></td><td>Raposo Pereira et al., 2018</td><td>27 subjects</td></tr><tr><td></td><td></td><td>Bell and Collins, 2011</td><td>19 subjects</td></tr></tbody></table>
## Gamma-hydroxybutyrate/Gamma-butyrolactone

Gammahydroxybutyrate is a central nervous system depressant that has a double stimulant and sedative effect (Raposo Pereira et al., 2019b). GBL, which is cheaper, is taken orally in liquid form and transformed into GHB (Busardo et al., 2018).

Gamma-butyrolactone/gamma-hydroxybutyrate is most often mixed with another drink. The sought-after effects are relaxation, disinhibition, increased desire and sensuality, and easier penetration. The main acute risk is overdose with significant sleepiness and hypothermia that can lead to coma and death.

An increase in the number of deaths in London related to GHB use was observed between 2011 and 2015 with 61 reported deaths, while a 119% increase in deaths between 2014 and 2015 was observed versus 25% for cocaine (Hockenhull et al., 2017). Regular GBL/GHB consumption and repeated comas alter cognitive functions, particularly memory (Raposo Pereira et al., 2018) and emotion management (Raposo Pereira et al., 2019a; Table 3). GBL/GHB dependence can be established using physical and psychological criteria with consumption outside of sexual intercourse.

## Ketamine, Cocaine, and Speed

Ketamine, an anesthetic used in human or veterinary medicine, is a phencyclidine (PCP) derivative that blocks non-competitively the glutamate N-methyl-D-aspartate (NMDA) receptor (Corazza et al., 2013). It is used as a psychoactive substance in sexual sessions for its euphoric effects. It can cause hallucinations at higher doses. Urologic complications are described with ketamine. Cases of bladder dysfunction have been reported in the literature, mainly ulcerative cystitis. Cases of hydronephrosis have also been reported. Symptoms described by users are frequency and urgency of urination, dysuria, urge incontinence, and occasionally painful hematuria (Morgan and Curran, 2012).

Cocaine and speed are still used in a sexual context but less frequently since the advent of the new designer drugs (Busardo et al., 2019).

## Erectile Dysfunction Agents

Non-psychoactive substances such as erectile dysfunction agents (sildenafil, tadalafil, and vardenafil) are used to facilitate or enhance sexual performances. These drugs are diverted from their medical use to counterbalance the negative effects of psychoactive drugs and to prolong the duration of sexual intercourse (Giorgetti et al., 2017). Combining all these drugs is associated with high cardiac toxicity (Bracchi et al., 2015).

## STI AND BBV

In addition to the complications already described, the major risks are related to the sexual behaviors of the users, and the injection of drugs that increases the risk of spreading BBV and STI.

Use of illicit and licit drugs in party and play is dramatically associated with high-risk sexual behaviors. Use

of methamphetamine is strongly associated with condomless anal intercourses (Fisher et al., 2011), multiple sex partners (Melendez-Torres et al., 2018a), sex marathons, and sex with HIV-positive MSM (Benotsch et al., 2012; Bui et al., 2018). The prevalence of hepatitis B, syphilis (Rana et al., 2019), and HIV is higher in men who use methamphetamine and Viagra which is associated with serodiscordant unprotected sexual intercourse (Spindler et al., 2007). Hepatitis C seroprevalence is higher in HIV-positive MSM who declared they practiced slamming, chemsex, and fisting (Vaux et al., 2019). Other STIs such as gonorrhea have increased with methamphetamine and GHB/GBL use (Kohli et al., 2019) and there has been a worldwide increase in all STIs among MSM that is linked to chemsex and Internet, which facilitates high-risk sexual behaviors (Soriano and Romero, 2018).

## PREVENTION AND INTERVENTION

Phone applications would be ideal to promote messages in terms of sexual health, STI and prevention of addictions. Some applications have started to emit HIV prevention messages (Chan et al., 2016). Medina et al. (2019) explained that future HIV prevention approach should pass through dating applications. Moreover another study showed that interventions that facilitate condom negotiation could exist in future applications (Tang et al., 2016).

Providing care to individuals suffering from the problematic practice of chemsex is complex; there are no explicit recommendations on specific drugs that could be used for withdrawal or regulation and the care must simultaneously take into account pharmacological, addictological, and psychological and sexual aspects. The use of integrative and specific interventions is necessary. Different types of therapy are tested as cognitive behavior therapy, contingency management, and gay-specific cognitive behavior therapy (GCBT). These therapies are used with or without medications for withdrawal or maintaining abstinence. GCBT integrated elements from standard cognitive behavior therapy with cultural and social elements of chemsex users. Reback has proved the efficiency of this therapy in methamphetamines users in the United States (Reback and Shoptaw, 2014). CBT and motivation interview improve adherence to HIV medication in gay and bisexual men (Parson et al., 2018).

For GBL/GHB withdrawal, the most used drugs are benzodiazepines, neuroleptics, and sometimes barbiturates (Cappetta and Murnion, 2019). Serious complications may occur with these, including hallucinations, delusions, and epileptic fits (Liao et al., 2018; Neu, 2019). Baclofen has been tested for the long-term maintenance of GBL/GHB abstinence, but randomized studies are required before specific recommendations can be issued (Beurmanjer et al., 2018).

Drugs such as atypical antidepressants (mirtazapine) or naltrexone have been tested to reduce sexual risk-taking and metamphetamine use (Knight et al., 2019).

Fighting against the transmission of infections requires preventive interventions and harm reduction including condom
distribution and needle exchange programs. These practices need to be developed.

Special attention should be paid to MSM with problematic chemsex behavior so they may have access to the best possible post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) (Hammoud et al., 2018; Sewell et al., 2019).

Actions focusing on prevention, addiction management and sexual health need to be increased and new community spaces such as sexual health centers need to be opened to break down barriers and help alleviate the shame of chemsex drug users (Giorgetti et al., 2017; Sewell et al., 2018).

order to embrace their sexual preferences, and others still for the effects of the drugs.

The phenomenon can be a claim of part of the MSM population that wants to have unbridled sex with protection against HIV. There is still enormous stigma and shame associated with HIV infection and being homosexual (Dubov et al., 2018). With chemsex, caregivers are confronted with a continuum between normal and pathological sexual and drug use behaviors. The care to be provided to chemsex users must be validated by large sample studies. CGBT and LGBT-specific-e-therapy (Lucassen et al., 2018) are interesting ways to facilitate prevention and access to care for problematic chemsex users.

## CONCLUSION

Chemsex is a complex issue. The behavior is at the crossroads of sociology, infectious medicine, addiction, and sexology. Its users are confronted with medical, psychiatric, and sexual risks. Some users engage in chemsex seeking sexual disinhibition, others in

## AUTHOR CONTRIBUTIONS

HD-R and HP reviewed the literature and wrote the manuscript. LK and AB revised the manuscript. All authors contributed equally to this manuscript.

## REFERENCES

Batisse, A., Fortias, M., Bourgogne, E., Grégoire, M., Sec, I., and Djezzar, S. (2014). Case series of 21 synthetic cathinones abuse. *J. Clin. Psychopharmacol.* 34, 411–413. doi: 10.1097/jcp.0000000000000116

Bell, J., and Collins, R. (2011). Gamma-butyrolactone (GBL) dependence and withdrawal. *Addiction* 106, 442–447. doi: 10.1111/j.1360-0443.2010.03145.x

Benotsch, E. G., Lance, S. P., Nettles, C. D., and Koester, S. (2012). Attitudes toward methamphetamine use and HIV risk behavior in men who have sex with men. *Am. J. Addict.* 21, S35–S42. doi: 10.1111/j.1521-0391.2012.00294.x

Beurmanjer, H., Kamal, R. M., de Jong, C. A. J., Dijkstra, B. A. G., and Schellekens, A. F. A. (2018). Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. *CNS Drugs* 32, 437–442. doi: 10.1007/s40263-018-0516-6

Bourne, A., Reid, D., Hickson, F., Torres-Rueda, S., and Weatherburn, P. (2015). Illicit drug use in sexual setting (« Chemsex ») and HIV/STI transmission risk behaviour among gay men in south London: findings from a qualitative study. *Sex. Trans. Infect.* 91, 564–568. doi: 10.1016/j.drugpo.2015.07.013

Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., and Boffito, M. (2015). Increasing use of « party drugs » in people living with HIV on antiretrovirals: a concern for patient safety. *AIDS* 29, 1585–1592. doi: 10.1097/QAD.0000000000000786

Bui, H., Zablotska-Manos, I., Hammoud, M., Jin, F., Lea, T., Bourne, A., et al. (2018). Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: results from the FLUX study. *Int. J. Drug Pol.* 55, 222–230. doi: 10.1016/j.drugpo.2018.01.018

Busardo, F. P., Gottardi, M., Pacifici, R., Vari, M. R., Tini, A., Volpe, A. R., et al. (2019). Nails analysis for drugs used in the context of chemsex: a pilot study. *J. Anal. Toxicol.* doi: 10.1093/jat/bkz009 [Epub ahead of print].

Busardo, F. P., Gottardi, M., Tini, A., Minutillo, A., Sirignano, A., Marinelli, E., et al. (2018). Replacing GHB with GBL in recreational setting: a new trend in Chemsex. *Curr. Drug Metab* 19, 1080–1085. doi: 10.2174/1389200219666180925090834

Busardo, F. P., Kyriakou, C., Napoletano, S., Marinelli, E., and Zaami, S. (2015). Mephedrone related fatalities: a review. *Eur. Rev. Med. Pharmacol. Sci.* 19, 3777–3790.

Cappetta, M., and Murnion, B. P. (2019). Inpatient management of gamma-hydroxybutyrate withdrawal. *Austr. Psychiatry* 27, 284–287. doi: 10.1177/1039856218822748

Chan, P. A., Towey, C., Poceta, J., Rose, J., Bertrand, T., Kantor, R., et al. (2016). Online Hookup sites for meeting sexual partners among men who have sex with men in Rhode Island, 2013: a call for public health action. *Publ. Health Rep.* 131, 264–271. doi: 10.1177/003335491613100210

Coppola, M., and Mondola, R. (2012). Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as « bath salts » or « plant food ». *Toxicol. Lett.* 211, 144–149. doi: 10.1016/j.toxlet.2012.03.009

Corazza, O., Assi, S., and Schifano, F. (2013). From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. *CNS Neurosci. Ther.* 19, 454–460. doi: 10.1111/cns.12063

Dargan, P. I., Sedefov, R., Gallegos, A., and Wood, D. M. (2011). The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). *Drug. Test. Anal.* 3, 454–463. doi: 10.1002/dta.312

Degenhardt, L., Mathers, B., Guarinieri, M., Panda, S., Phillips, B., Strathdee, S. A., et al. (2010). Reference group to the United Nations on HIV and injecting drug use. Meth/amphetamine use and associated HIV: implications for global policy and public health. *Int. J. Drug Pol.* 21, 347–358. doi: 10.1016/j.drugpo.2009.11.007

Diestelmann, M., Zangl, A., Herrle, I., Koch, E., Graw, M., and Paul, L. D. (2018). MDPV in forensic routine cases: psychotic and aggressive behavior in relation to plasma concentrations. *Forensic Sci. Int.* 283, 72–84. doi: 10.1016/j.forsciint.2017.12.003

Dubov, A., Galbo, P., Altice, F. L., and Fraenkel, L. (2018). Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. *Am. J. Mens Health.* 12, 1843–1854. doi: 10.1177/1557988318797437

Edmundson, C., Heinsbroek, E., Glass, R., Hope, V., Mohammed, H., White, M., et al. (2018). Sexualised drug use in the United Kingdom (UK): a review of the literature. *Int. J. Drug Pol.* 55, 131–148. doi: 10.1016/j.drugpo.2018.02.002

Elliot, E. R., Singh, S., Tyebally, S., Gedela, K., and Nelson, M. (2017). Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity. *HIV Med.* 18, 525–531. doi: 10.1111/hiv.12487

Ezaki, J., Ro, A., Hasegawa, M., and Kibayashi, K. (2016). Fatal overdose from synthetic cannabinoids and cathinones in Japan: demographics and autopsy findings. *Am. J. Drug Alcohol Abuse* 42, 520–529. doi: 10.3109/00952990.2016.1172594

Fisher, D. G., Reynolds, G. L., Ware, M. R., and Napper, L. E. (2011). Methamphetamine and Viagra use: relationship to sexual risk behaviors. *Arch. Sex. Behav.* 40, 273–279. doi: 10.1007/s10508-009-9495-5

Forsyth, A. J. (2012). Virtually a drug scare: mephedrone and the impact of the internet on drug news transmission. *Int. J. Drug Pol.* 23, 198–209. doi: 10.1016/j.drugpo.2011.12.003

Froberg, B. A., Levine, M., Beuhler, M. C., Judge, B. S., Moore, P. W., Engebretsen, K. M., et al. (2015). Acute methylenedioxypyrovalerone toxicity. *J. Med. Toxicol.* 11, 185–194. doi: 10.1007/s13181-014-0446-8
Garofalo, R., Herrick, A., Mustanski, B. S., and Donenberg, G. R. (2007). Tip of the
iceberg: young men who have sex with men, the Internet, and HIV risk. *Am. J.
Public Health* 97, 1113–1117. doi: 10.2105/ajph.2005.075630

Gilbart, V. L., Simms, I., Jenkins, C., Furegato, M., Gobin, M., Oliver, I., et al. (2015). Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with *Shigella flexneri* 3a in England and Wales. *Sex Transm. Infect.* 91, 598–602. doi: 10.1136/sextrans-2015-052014

Giorgetti, R., Tagliabracci, A., Schifano, F., Zaami, S., Marinelli, E., and Busardo, F. P. (2017). When « Chems » meet sex: a rising phenomenon called « ChemSex ». *Curr. Neuropharmacol.* 15, 762–770. doi: 10.2174/1570159X156661117151148

Grov, C., Breslow, A. S., Newcomb, M. E., Rosenberger, J. G., and Bauermeister, J. A. (2014). Gay and bisexual men's use of the internet: research from the 1990s through *J. Sex Res.* 51, 390–409. doi: 10.1080/00224499.2013.871626

Hammoud, M. A., Vaccher, S., Jin, F., Bourne, A., Haire, B., Maher, L., et al. (2018). The new MTV generation: using metamphetamines. *TruvadaTM, and ViagraTM to enhance sex and stay safe. *Int. J. Drug Pol.* 55, 197–204. doi: 10.1016/j.drugpo.2018.02.021

Heinsbroek, E., Glass, R., Edmundson, C., Hope, V., and Desai, M. (2018). Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs attending services in England, Wales and Northern Ireland, 2013-2016. *Int. J. Drug Pol.* 55, 215–221. doi: 10.1016/j.drugpo.2018.02.017

Hockenhull, J., Murphy, K. G., and Paterson, S. (2017). An observed rise in γ-hydroxybutyrate-associated deaths in London: evidence to suggest a possible link with concomitant rise in chemsex. *Forensic Sci. Int.* 270, 93–97. doi: 10.1016/j.forsciint.2016.11.039

Kalix, P. (1990). Pharmacological properties of the stimulant khat. *Pharmacol. Ther.* 48, 397–416. doi: 10.1016/0163-7258(90)90057-9

Knight, R., Karamouzian, M., Carson, A., Edward, J., Carrieri, P., Shoveller, J., et al. (2019). Interventions to address substance use and sexual risk among gay, bisexual and other men who have sex with men who use amphetamines: a systematic review. *Drug Alcohol Depend* 194, 410–429. doi: 10.1016/j.drugalcdep.2018.09.023

Kohli, M., Hickson, F., Free, C., Reid, D., and Weatherburn, P. (2019). Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in UK. *Sex Health* doi: 10.1071/SH18159 [Epub ahead of print].

Kronstrand, R., Guerrieri, D., Vikingsson, S., Wohlfarth, A., and Green, H. (2018). Fatal poisonings associated with new psychoactive substances. *Handb. Exp. Pharmacol.* 252, 495–541. doi: 10.1007/164_2018_110

Lawn, W., Aldridge, A., Xia, R., and Winstock, A. R. (2019). Substances-linked
sex in heterosexual, homosexual, and bisexual men and women: an online,
cross-sectional « global drug survey » report. *J. Sex Med.* 16, 721–732. doi:
10.1016/j.jsxm.2019.02.018

Lewnard, J. A., and Berrang-Ford, L. (2014). Internet-based partner selection and risk for unprotected anal intercourse in sexual encounters among men who have sex with men: a meta-analysis of observational studies. *Sex Transm. Infect.* 90, 290–296. doi: 10.1136/sextrans-2013-051332

Liao, P. C., Chang, H. M., and Chen, L. Y. (2018). Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol. *J. Formos. Med. Assoc.* 117, 1124–1127. doi: 10.1016/j.jfma.2018.06.005

Liechti, M. (2015). Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. *Swiss Med. Wkly.* 145:w14043. doi: 10.4414/smw.2015.14043

Lucassen, M., Samra, R., Iacovides, I., Fleming, T., Shepherd, M., Stasiak, K., et al. (2018). How LGBT+ young people use the Internet in relation to their mental health and envisage the use of e-therapy: exploratory study. *JMIR Serious Games* 6:e11249. doi: 10.2196/11249

Maxwell, S., Shahmanesh, M., and Gafos, M. (2019). Chemsex behaviours among men who have sex with men: a systematic review of the literature. *Int. J. Drug Pol.* 63, 74–89. doi: 10.1016/j.drugpo.2018.11.014

McKetin, R., Dean, O. M., Turner, A., Kelly, P. J., Quinn, B., Lubman, D. I., et al. (2019). A study protocol for the N-ICE trial: a randomized double-blind placebo controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (“ice”) dependence. *Trials* 20:325. doi: 10.1186/s13063-019-3450-0

McKetin, R., Lunman, D. I., Baker, A. L., Dawe, S., and Ali, R. L. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. *JAMA Psychiatry* 70, 319–324. doi: 10.1001/jamapsychiatry.2013.283

Medina, M. M., Crowley, C., Montgomery, M. C., Tributino, A., Almonte, A., Sowemimo-Coker, G., et al. (2019). Disclosure of HIV serostatus and pre-exposure prophylaxis use on internet hookup sites among men who have sex with men. *AIDS Behav.* 23, 1681–1688. doi: 10.1007/s10461-018-2286-z

Melendez-Torres, G. J., Bourne, A., Hickson, F., Reid, D., and Weatherburn, P. (2018a). Correlates and subgroups of injecting drug use in UK gay and bisexual men: findings from the 2014 gay men's sex survey. *Drug Alcohol Depend.* 187, 292–295. doi: 10.1016/j.drugalcdep.2018.03.014

Melendez-Torres, G. J., Bourne, A., Reid, D., Hickson, F., Bonell, C., and Weatherburn, P. (2018b). Typology of drug use in United Kingdom men who have sex with men and associations with socio-sexual characteristics. *Int. J. Drug Pol.* 55, 159–164. doi: 10.1016/j.drugpo.2018.01.007

Morgan, C. J., and Curran, H. V. (2012). Ketamine use: a review. *Addiction* 107, 27–38. doi: 10.1111/j.1360-0443.2011.03576.x

Neeki, M. N., Dong, F., Liang, L., Toy, J., Carrico, B., Jabourian, N., et al. (2018). Evaluation of the effect of methamphetamine on traumatic injury complications and outcomes. *Addict Sci. Clin. Pract.* 13, 11. doi: 10.1186/s13722-018-0112-6

Neu, P. (2019). Course and complications of GHB detoxification treatment a 1-year case series. *Nervenarzt* 90, 509–515. doi: 10.1007/s00115-018-0636-8

O'Connor, A. D., Padilla-Jones, A., Gerkin, R. D., and Levine, M. (2015). Prevalence of rhabdomyolysis in sympathomimetic toxicity: a comparaison of stimulants. *J. Med. Toxicol.* 11, 195–200. doi: 10.1007/s13181-014-0451-y

Papaseit, E., Olesti, E., de la Torre, R., Torrens, M., and Farre, M. (2017). Mephedrone concentrations in cases of clinical intoxication. *Curr. Pharm. Des.* 23, 5511–5522. doi: 10.2174/1381612823666170704130213

Parson, J. T., John, S. A., Millar, B. M., and Starcks, T. J. (2018). Testing the efficacy of combined motivation interview and cognitive behavioral skills training to reduce methamphetamine use and improve HIV medication adherence among HIV-positive gay and bisexual men. *AIDS Behav.* 22, 2674–2686. doi: 10.1007/s10461-018-2086-5

Penders, T. M., Gestring, R. E., and Vilensky, D. A. (2012). Excited delirium following use of synthetic cathinones (bath salts). *Gen. Hosp. Psychiatry* 34, 647–650. doi: 10.1016/j.genhosppsych.2012.06.005

Petit, A., Karila, L., Sananes, M., and Lejoyeux, M. (2013). Mephedrone: a new synthetic drug. *Press Med.* 42, 1310–1316. doi: 10.1016/j.lpm.2012.11.019

Rana, S., Macdonald, N., French, P., Jarman, J., Patel, S., Portman, M., et al. (2019). Enhanced surveillance of syphilis cases among men who have sex with men in London, October 2016-January 2017. *Int. J. Std. Aids* 30, 422–429. doi: 10.1177/0956462418814998

Raposo Pereira, F., McMaster, M. T. B., de Vries, Y. D. A. T., Polderman, N., van den Brink, W., and van Wingen, G. A. (2019b). Influence of gamma-hydroxybutyric acid-use and gamma-hydroxybutyric acid-induced coma on affect and the affective network. *Eur. Addict. Res.* 25, 173–181. doi: 10.1159/000497381

Raposo Pereira, F., McMaster, M. T. B., Polderman, N., de Vries, Y. D. A. T., van den Brink, W., and van Wingen, G. A. (2018). Adverse effects of GHB-induced coma on long-term memory and realted brain function. *Drug Alcohol Depend* 190, 29–36. doi: 10.1016/j.drugalcdep.2018.05.019

Raposo Pereira, F., McMaster, M. T. B., Schellekens, A., Polderman, N., de Vries, Y. D. A. T., van den Brink, W., et al. (2020). Effects of recreational GHB and multiple GHB-induced comas on brain structure and impulsivity. *Front. Psychiatry.* 11:166. doi: 10.3389/fpsyt.2020.00166

Raposo Pereira, F., Zhutovsky, P., Mcmaster, M. T. B., Polderman, N., de Vries, Y. D. A. T., van den Brink, W., et al. (2019a). Recreational use of GHB is associated with alterations of resting state functional connectivity of the central executive and default mode networks. *Hum. Brain Mapp.* 40, 2413–2421. doi: 10.1002/hbm.24532

Reback, C. J., and Soptaw, S. (2014). Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. *Addict. Behav.* 39, 1286–1291. doi: 10.1016/j.addbeh.2011.11.029

Renninger, N. J. (2018). Grindr killed the gay bar, and other attempts to blame social technologies for urban development: a democratic approach to popular
technologies and queer sociality. *J. Homosex*. 17, 1–20. doi: 10.1080/00918369. 2018.1514205

Riley, A. L., Nelson, K. H., To, P., Lopez-Arnau, R., Xu, P., Wang, D., et al. (2019). Abuse potential and toxicity of the synthetic cathinones (i.e., « *Bath salts* »). *Neurosci. Biobehav. Rev.* doi: 10.1016/j.neurobiorev.2018.07.015 [Epub ahead of print].

Rommel, N., Rohleder, N. H., Koerdt, S., Wagenpfeil, S., Härtel-Petri, R., Wolf, K. D., et al. (2016). Sympathomimetic effects of chronic methamphetamine abuse on oral health: a cross-sectional study. *BMC Oral Health* 16:59. doi: 10.1186/s12903-016-0218-8

Sande, M. (2016). Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. *Int. J. Drug Pol.* 27, 65–73. doi: 10.1016/j.drugpo.2015.03.005

Schmidt, A. J., Bourne, A., Weatherburn, P., Reid, D., Marcus, U., Hickson, F., et al. (2016). Illicit drug use among gay and bisexual men in 44 cities: findings from the European MSM internet survey (EMIS). *Int. J. Drug Pol.* 38, 4–12. doi: 10.1016/j.drugpo.2016.09.007

Schmoll, S., Romanek, K., Stich, R., Bekka, R., Stenzl, J., Geith, S., et al. (2018). An internet-based survey of 96 german-speaking users of “bath salts”: frequent complications, risky sexual behavior, violence, and delinquency. *Clin. Toxicol.* 56, 219–222. doi: 10.1080/15563650.2017.1353094

Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., et al. (2007). Neurocognitive effects of methamphetamines: a critical review and meta-analysis. *Neuropsychol. Rev.* 17, 275–297. doi: 10.1007/s11065-007-9031-0

Serre, A., Vuillot, O., Eiden, C., Gambier, J., Berger, A., Mathieu, O., et al. (2019). Acute Psychiatric Disorders Related to fake Cathinones: Ephylone. *J. Anal. Toxicol.* 43, e1–e2. doi: 10.1093/jat/bkz020

Sevak, R. J., Vansickel, A. R., Stoops, W. W., Glaser, P. E. A., Hays, L. R., and Rush, C. R. (2011). Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in human pretreated with aripiprazole. *J Clin. Psychopharmacol.* 31, 470–480. doi: 10.1097/JCP.0b013e318221 b2db

Sewell, J., Cambiano, V., Miltz, A., Speakman, A., Lampe, F. C., Philipes, A., et al. (2018). Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013-2016. *Sex Transm. Infect.* 94, 494–501. doi: 10.1136/sextrans-2017-053439

Sewell, J., Cambiano, V., Speakman, A., Lampe, F. C., Phillips, A., Stuart, D., et al. (2019). Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study. *Int. J. Drug Policy.* 68, 54–61. doi: 10.1016/j.drugpo.2019.03.021

Shetty, V., Harrell, L., Murphy, D. A., Vitero, S., Gutierrez, A., Belin, T. R., et al. (2015). Dental disease patterns in methamphetamine users: findings in a large urban sample. *J. Am. Dent. Assoc.* 146, 875-885.

Soriano, V., and Romero, J. D. (2018). Rebound in sexually transmitted infections following the success of antiretrovirals for HIV/AIDS. *AIDS Rev.* 20, 187–204. doi: 10.2487/AIDSRev.18000034

Spiller, H. A., Ryan, M. L., Weston, R. G., and Jansen, J. (2011). Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. *Clin. Toxicol.* 49, 499–505. doi: 10.3109/ 15563650.2011.590812

Spindler, H. H., Scheer, S., Chen, S. Y., Klausner, J. D., Katz, M. H., Valleroy, L. A., et al. (2007). Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM. *San Francisco. Sex Transm Dis.* 34, 586–591. doi: 10.1097/01.olq.0000258339.17325.93

Tang, W., Best, J., Zhang, Y., Liu, F. Y., Tso, L. S., Huang, S., et al. (2016). Gay mobile apps and the evolving virtual risk environment: a cross-sectional online survey among men who have sex with men in China. *Sex Transm. Infect.* 92, 508–514. doi: 10.1136/sextrans-2015-052469

Umebachi, R., Aoki, H., Sugita, M., Taira, T., Wakai, S., Saito, T., et al. (2016). Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. *Clin. Toxicol.* 54, 563–567. doi: 10.3109/15563650.2016.1166508

Vaux, S., Chevaliez, S., Saboni, L., Sauvage, C., Sommen, C., Barin, F., et al. (2019). Prevalence of hepatitis C infection, screening and associated factors among men who have sex with men attending gay venues: a cross-sectional survey (PREVAGAY), France 2015. *BMC Infect. Dis.* 19:315. doi: 10.1186/s12879-019-3945-z

Whitfield, D. L., Kattari, S. K., Walls, N. E., and Al-Tayyib, A. (2017). Grindr, Scruff, and on the hunt: predictors of condomless anal sex, Internet use, and mobile application use among men who have sex with men. *Am. J. Mens. Health* 11, 775–784. doi: 10.1177/1557988316687843

Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., and Marsden, J. (2011). Mephedrone: use, subjective effects and health risks. *Addiction* 106, 1991–1996. doi: 10.1111/j.1360-0443.2011.03502.x

Wood, D. M., Greene, S. L., and Dargan, P. I. (2013). Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. *Eur. J. Emerg. Med.* 20, 263–267. doi: 10.1097/MEJ.0b013e3283573115

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Donnadieu-Rigole, Peyrière, Benyamina and Karila. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.